Heska Corp  

(Public, NASDAQ:HSKA)   Watch this stock  
Find more results for HSKA
+0.68 (0.85%)
Real-time:   2:08PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 79.49 - 81.63
52 week 75.21 - 115.00
Open 79.63
Vol / Avg. 17,188.00/76,862.00
Mkt cap 581.55M
P/E 42.29
Div/yield     -
EPS 1.90
Shares 7.24M
Beta 0.74
Inst. own 83%
Nov 2, 2017
Q3 2017 Heska Corp Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 9.81% 9.35%
Operating margin 12.02% 12.71%
EBITD margin - 16.28%
Return on average assets 9.44% 10.11%
Return on average equity 12.52% 13.96%
Employees 327 -
CDP Score - -


3760 Rocky Mountain Ave
LOVELAND, CO 80538-7084
United States - Map
+1-970-4937272 (Phone)
+1-970-6193003 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products. Its OVP segment includes private label vaccine and pharmaceutical production for cattle but also for other species, including equine, porcine, avian, feline and canine. All OVP products are sold by third parties under third-party labels. It focuses on supporting veterinarians in canine and feline healthcare space. It offers a line of veterinary blood testing and other instruments. It manufactures biological and pharmaceutical products for other animal health companies.

Officers and directors

Sharon J. Larson Independent Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Kevin S. Wilson President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Catherine Grassman Principal Financial Officer, Principal Accounting Officer, Vice President, Controller
Age: 41
Bio & Compensation  - Reuters
Michael J. McGinley Ph.D. President - Biologicals & Pharmaceuticals
Age: 56
Bio & Compensation  - Reuters
Jason A. Napolitano Chief Operating Officer, Chief Strategist and Secretary
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Steven M. Eyl Executive Vice President - Global Sales and Marketing
Age: 51
Bio & Compensation  - Reuters
Steven M. Asakowicz Executive Vice President - Companion Animal Health Sales
Age: 51
Bio & Compensation  - Reuters
Rodney A. Lippincott Executive Vice President - Companion Animal Health Sales
Age: 43
Bio & Compensation  - Reuters
Nancy Wisnewski Ph.D. Executive Vice President - Diagnostic Operations and Product Development
Age: 54
Bio & Compensation  - Reuters
Scott Humphrey Director
Bio & Compensation  - Reuters